Supplementary Figure 2 from Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt; Mutation